Single or Repeat Dose of G03-52-01 in Adult Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

625

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

February 4, 2025

Study Completion Date

February 4, 2025

Conditions
HealthyBotulinum Toxin
Interventions
DRUG

G03-52-01

G03-52-01 administered intramuscularly

DRUG

Placebo

placebo

Trial Locations (15)

23502

AMR Norfolk, Norfolk

33134

AMR Miami, Miami

33912

AMR Fort Myers, Fort Myers

36608

AMR Mobile, Mobile

37909

AMR Knoxville West, Knoxville

40509

AMR Lexington, Lexington

64114

AMR Kansas City, Kansas City

67042

AMR El Dorado, El Dorado

67114

AMR Newton, Newton

67205

AMR Wichita West, Wichita

67207

AMR Wichita East, Wichita

70119

AMR New Orleans, New Orleans

73069

AMR Norman, Norman

85281

AMR Tempe, Tempe

89119

AMR Las Vegas, Las Vegas

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Alachua Government Services, Inc.

INDUSTRY